Version history

{
  "session_id": "sess_ana_0847737b-b8f3-4130-b_20260428_055352",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "content": "\n\n## Translational Feasibility Assessment\n\n### Druggability and Target Accessibility\n\nThe proposed communication networks involve **multiple tractable targets**:\n- **MCT1/4 (SLC16A3/4)**: AZD3965 (AstraZeneca) completed Phase I/II oncology trials; blood-brain barrier penetration is moderate but achievable with structural analogs (PMID: 29438599)\n- **SEMA3A-PLEXIN axis**: Receptor tyrosine kinase signaling is druggable via biologics; however, semaphorins have developmental CNS roles raising safety concerns\n- **NRG1-ERBB4**: ErbB kinase inhibitors exist (lapatinib, neratinib), though systemic ErbB blockade carries cardiac toxicity (Erbb2-dependent embryogenesis; PMID: 23023333)\n\n### Safety Signals\n\n- **LIF pathway**: Clinical-grade LIF inhibitors have not been developed for neurodegeneration; systemic LIF modulation risks immune dysregulation (PMID: 31330545)\n- **MCT inhibitors**: AZD3965 showed GI toxicity and asymptomatic lymphopenia in cancer trials (NCT01791595); CNS-specific safety uncharacterized\n- **Sulfatase inhibition**: No CNS-targeted sulfatase inhibitors exist in clinical development; off-target effects on FGF/Wnt signaling pose unknown risks\n\n### Competitive Landscape\n\nLundbeck and others are exploring **LIF pathway modulation** in ALS/MS (preclinical). MCT inhibition for neuroprotection is earlier-stage. No competitor targets the oligodendrocyte-astrocyte spatial interface specifically.\n\n### Translational Readiness Score: **0.38**\n\n**Most Critical Unresolved Barrier**: **Unproven causal direction of OPC dysfunction**. The mechanistic chain (sulfatase expression → enhanced tau uptake → propagation) is correlative. Fünfschilling et al. (PMID: 23023333) demonstrates oligodendrocyte autonomy in glycolysis, undermining the metabolic coupling assumption. Critically, conditional *Mct4* knockout phenotypes and OPC-specific Sulf1/2 genetic ablation have not been performed in AD models.\n\n**Recommendation**: Prioritize OPC-specific Sulf1/2 conditional knockout in 5xFAD or MAPT knock-in models before therapeutic investment. Demonstrate that OPC sulfatase loss attenuates entorhinal-to-hippocampal tau spread by longitudinal PET—this single experiment would transform the translational readiness score to >0.6.",
  "evidence_cited": "[\"PMID:21592797\", \"DOI:10.1016/j.celrep.2021.109247).\", \"DOI:10.1016/j.cell.2020.05.002).\", \"DOI:10.1038/s41586-023-06185-3)\", \"DOI:10.1016/j.neuron.2022.04.014).\", \"PMID:23023333\", \"DOI:10.1016/j.brainres.2021.147511)\", \"DOI:10.1016/j.neuron.2019.01.045).\", \"PMID:29438599\", \"PMID:31330545\", \"DOI:10.1016/j.neurobiolaging.2021.09.012).\", \"DOI:10.1073/pnas.2218898120),\", \"DOI:10.1038/s41586-018-0191-2),\", \"DOI:10.1016/j.cel.2023.02.011).\", \"DOI:10.1016/j.neuron.2017.10.029)\"]",
  "tokens_used": "561"
}